Within the metabolic pathways influenced by ML, a select group of differentially regulated proteins serve as critical junctions in these pathways and are likely to be key targets for ML’s therapeutic action on T2D, these include Acsl1, Acox1, Slc25a1, Pdhb, Anxa1, and Apoa1, which are considered potential targets for ML’s intervention. This evidence concerns the gene APOA1 and type 2 diabetes mellitus.